Evidence map›Paper›PMID 39886965›Full record

ReviewOncology reports2025

Role of miRNA‑145‑5p in cancer (Review).

Zeshan Chen, Yijue Qin

Abstract readReview
In one paragraph

Review in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. The Impact ofBiomedicines · 2025
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zeshan ChenDepartment of Traditional Chinese Medicine, Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi 530016, P.R. China.
Yijue QinDepartment of Traditional Chinese Medicine, Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi 530016, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA‑145‑5p (miRNA‑145‑5p) is a short non‑coding RNA located at chromosome 5q33.1, which has gained significant attention in several aspects of cellular regulation and biological functions. In malignant tumours, miRNA‑145‑5p may function as either a tumour suppressor or an oncogene, affecting tumour progression by targeting downstream genes or modulating their expression through upstream regulators. However, the full extent of miRNA‑145‑5p's role in cancer has remained to be determined. This review provides an overview of the role of miRNA‑145‑5p in cancer, investigates its potential as a biomarker for diagnosis, prognosis and treatment response, and evaluates its influence on cancer chemotherapy and radiotherapy. Finally, current strategies for systemic delivery of miRNA‑145‑5p in cancer therapies are summarized.

Indexed as

Biomarkers, TumorMicroRNAsNeoplasmsGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorMicroRNAsbiomarkerscancerchemotherapydelivery systemsdiagnosticsmiRNA‑145‑5pprognosticsvector

Identifiers

PMID39886965
PMCPMC11800069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.